NurExone's Intellectual Property Portfolio Expands

Innovations and know-how in exosome production suited for many clinical applicationsTORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies. NurExone’s Intellectual

Related Keywords

Germany ,Israel ,Toronto ,Ontario ,Canada ,Shulamit Levenberg ,Lior Shaltiel ,Eva Reuter ,Technion Center ,Nurexone Biologic Inc ,National Phases ,Company Or Nurexone ,Venture Exchange ,Technion Israel Institute Of Technology ,Thesis Capital Inc ,Regulation Services Provider ,Exone Biologic ,Intellectual Property ,Extracellular Vesicles ,Israel Institute ,Chief Scientific Advisor ,Central Nervous System ,Orphan Drug Designation ,Executive Officer ,Urexone Biologic Inc ,International Patent Application ,Iopharmaceutical Company ,Company ,Exosomes ,Development ,Omprehensive Technology ,